Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methimazole in Progressive Glioblastoma
NCT05607407Phase 2Suspended
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jan 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of methimazole in glioblastoma (GBM), glioma, sponsored by Case Comprehensive Cancer Center. Started Jan 2023; status: suspended.
02
Drugs
methimazole
03
Conditions
glioblastoma (GBM)glioma
Beyond the preview
Go deeper on NCT05607407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607407.